Molecular Scissors – Designing Prodrugs Activated by Tumor Enzymes

0:00Welcome to Creative Biolapse's podcast channel. Join us as we explore the cutting-edge science of targeted delivery systems that are revolutionizing medicine. Interested in the future of drug development? Subscribe now! Welcome to the Pharma Frontier. I'm Alex. In our last episode, Dr. Lena Cruz explained how the low-oxygen environment of tumors can be used to activate prodrugs. Today, we're moving to a strategy that seeks even greater precision, designing prodrugs that are unlocked by specific enzymes found at high levels in tumors. Dr. Cruz, why target enzymes? Hello, Alex. Enzymes offer a lock-in-key mechanism. Their activity is highly specific. Many tumors over-express certain proteases enzymes that cut peptide bonds as part of their invasive and metastatic behavior. If we design a prodrug that is a substrate for a tumor-associated protease, we can achieve very localized activation.

1:01So the logic is, find an enzyme that's very active at the tumor, then build a key that only it can turn. That's right. The goal is a prodrug that is completely stable in blood and healthy tissues, but is rapidly cleaved when it encounters the high concentration of these enzymes at the tumor site. What are some of the key tumor-associated enzymes targeted? Several families are prominent. Matrix metallic proteases are involved in breaking down the extracellular matrix, helping cancer spread. Cthepsin B, a lysosomal cysteine protease, is often elevated in tumors and linked to poor prognosis. Plasmann, a serine protease involved in blood clotting and tissue remodeling, is activated at high levels in many tumors. And for a very specific cancer type? A classic is prostate-specific antigen for prostate cancer. While it's present at low levels in the blood, it's highly active in the prostate tumor microenvironment, making it a great target. So how do you physically build a prodrug for these

2:06enzymes? Is it just a drug glued to a peptide? The core design is a three-part molecule. You have the active drug, a peptide linker, and often a spacer group. The peptide linker is a short sequence of amino acids, like a D or tripeptide, that is specifically recognized and cut by the target enzyme. The simplest design is to attach this peptide directly to the drug. Is that effective? Sometimes, but often it's not. A bulky drug molecule can physically block the enzyme from accessing the peptide bond it needs to cut. Think of it like trying to cut a piece of string with scissors when there's a big rock tied in the middle of it. That makes sense. Also, after cleavage, wouldn't the drug still have a piece of the peptide attached? Exactly. That's the second problem. The drug might be released with a piece of the peptide still attached, which could reduce its activity or change its properties.

3:07That's where the spacer comes in. The self-amulative spacer you mentioned before. Exactly. This is a brilliant piece of chemical engineering. The most common spacer is Parameno Benzil alcohol. You attach the peptide to the amine of the spacer and the drug to the alcohol of the spacer, often through a carbomate bond. So the enzyme cuts the bond between the peptide and the spacer? Yes. When the enzyme cleaves the peptide, it frees the amine group on the spacer. This amine group is electron-donating and triggers an instant intermolecular one six-elimination reaction. The spacer literally falls apart, releasing the pure, unmodified active drug in a small, harmless byproduct. So the enzyme just triggers the first domino and the spacer's own chemistry does the rest, cleanly releasing the drug. Precisely. It allows the enzyme to do its specific job without the drug getting in the way.

4:09For large, bulky drugs like doxarubicin or pachytaxyl, researchers have even used two or three of these spacer units in a row to move the drug even farther from the cleavage site, speeding up enzyme action dramatically. Can you give us a concrete example of this approach in action? Certainly. One well-studied system targets plasma. A pro-drug for doxarubicin was made using a peptide sequence that plasma recognizes linked to doxarubicin via the paraminobenzel alcohol spacer. This pro-drug was over 100 times less toxic to cells that didn't produce plasma. And in cells that did produce plasma? In cells engineered to produce high levels of plasma, it's toxicity match that of free doxarubicin. This demonstrates the concept of selective activation beautifully. You only get the full effect where the right enzyme is present. What about for kethypsin B? Similar strategies work.

5:10Researchers have made pro-drugs of combertastatin A4 and eta-poside using a valine citralline peptide linker, which is a good substrate for kethypsin B. These pro-drugs showed significantly reduced cytotoxicity until activated by the enzyme. The spacer technology is versatile and works with many drug enzyme combinations. And for a more restricted enzyme like prostate-specific antigen? PSA is a great example of tissue-specific targeting. Pro-drugs have been made where doxarubicin is linked to a PSA-specific heptipeptide. In PSA-producing prostate cancer cells, the drug is effectively released. In other cancer cells without PSA, it remains inert. This is the holy grail, activation only in the intended tissue. This all sounds highly targeted. But are these enzymes truly unique to tumors? Couldn't they be active somewhere else in the body at lower levels? That's the main limitation, Alex.

6:12You've hit the nail on the head. They are often overexpressed, not exclusive. Kethypsin B, for instance, exists in lysosomes of many normal cells. So, there's always a background risk of activation in healthy tissues, potentially causing side effects. So how do you get around that? Is there a way to achieve true exclusivity? To overcome this and achieve true specificity, scientists developed more radical two-step approaches. These methods don't rely on natural tumor enzymes at all. Instead, they deliver a unique activating enzyme directly to the tumor first. An enzyme that the human body has never seen before. That sounds like a game changer. You bring your own key to the lock. It is. These are the strategies known as antibody-directed enzyme-prodrug therapy and gene-directed enzyme-prodrug therapy. They allow us to use highly efficient, non-human enzymes and tailor-made

7:14prodrugs that are completely inert in the human body until they meet their matching enzyme at the tumor site. It's the ultimate in precision targeting. That's a phenomenal concept, delivering the key itself to create a completely unique lock. Today, we've seen the elegance of peptide linkers in self-amolative spacers, designs that use enzymes like Kethypsin B or PSA as precise triggers. This is targeting at the molecular level. It is, though we acknowledge the challenge, these enzymes aren't exclusive to tumors. Right, which is why the logical next step is so revolutionary. If you can't rely solely on what's already there, why not bring in something entirely new? Something the body has never seen before and place it exactly where you need it. That's the promise of the two-step approaches. And that's exactly where we're going next. In our fourth and final episode of this series on the pharma frontier, we will dive into adept in-depth. We'll explore how antibodies can guide bacterial enzymes to a tumor

8:17and how genes can turn cancer cells into drug-activating factories. It's the cutting edge of targeted therapy. These strategies represent a powerful convergence of drug design, immunology, and gene therapy. Thank you, Dr. Cruz, for unpacking these complex ideas with us. And thank you to our listeners for tuning in. Join us for the finale to complete our exploration of the prodrud promise.